Inga Zerr

Inga Zerr's AcademicInfluence.com Rankings

Inga Zerr

Medical

#3376

World Rank

#3844

Historical Rank

Neurology

#309

World Rank

#392

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Inga Zerr Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Inga Zerr's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Classification of sporadic Creutzfeldt‐Jakob disease based on molecular and phenotypic analysis of 300 subjects (1999) (1361)
Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease (2009) (782)
Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease (2000) (467)
Detection of 14‐3‐3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt‐Jakob disease (1998) (436)
Iatrogenic Creutzfeldt–Jakob disease at the millennium (2000) (419)
Genetic prion disease: the EUROCJD experience (2005) (403)
Quantifying prion disease penetrance using large population control cohorts (2016) (352)
Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease (1997) (331)
Mortality from Creutzfeldt–Jakob disease and related disorders in Europe, Australia, and Canada (2005) (329)
CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease (2006) (277)
Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. (2004) (261)
Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob disease. (2006) (261)
Accuracy and reliability of periodic sharp wave complexes in Creutzfeldt-Jakob disease. (1996) (254)
Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease (1999) (241)
Ultrasensitive detection of pathological prion protein aggregates by dual-color scanning for intensely fluorescent targets. (2000) (240)
Incidence and spectrum of sporadic Creutzfeldt–Jakob disease variants with mixed phenotype and co-occurrence of PrPSc types: an updated classification (2009) (219)
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry (2017) (209)
Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. (2000) (207)
MR imaging of Creutzfeldt-Jakob disease. (1996) (207)
Diagnostic value of periodic complexes in Creutzfeldt–Jakob disease (2004) (195)
MRI lesion profiles in sporadic Creutzfeldt–Jakob disease (2009) (194)
Descriptive epidemiology of Creutzfeldt‐Jakob disease in six european countries, 1993–1995 (1998) (188)
How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. (1999) (185)
α-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B (2017) (183)
Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993-95 (1998) (180)
Current clinical diagnosis in Creutzfeldt‐Jakob disease: Identification of uncommon variants (2000) (175)
The Heidenhain variant of Creutzfeldt-Jakob disease. (1999) (173)
Molecular genetics of human prion diseases in Germany (1999) (171)
Deletion of Cellular Prion Protein Results in Reduced Akt Activation, Enhanced Postischemic Caspase-3 Activation, and Exacerbation of Ischemic Brain Injury (2006) (171)
Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease (1995) (170)
Creutzfeldt-Jakob disease in Germany: a prospective 12-year surveillance. (2007) (165)
Decreased β-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (2000) (164)
Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease (2015) (156)
Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. (2010) (156)
Rapidly progressive Alzheimer disease. (2011) (150)
Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease (2001) (147)
Hashimoto’s encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease (1999) (146)
Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial (2014) (141)
Sporadic Creutzfeldt-Jakob disease (2004) (134)
Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt–Jakob disease and rapid dementias: a longitudinal multicentre study over 10 years (2012) (134)
Creutzfeldt-Jakob disease: comparative analysis of MR imaging sequences. (2006) (133)
Early Detection of Abnormal Prion Protein in Genetic Human Prion Diseases Now Possible Using Real-Time QUIC Assay (2013) (131)
Upregulation of cellular prion protein (PrPc) after focal cerebral ischemia and influence of lesion severity (2004) (131)
MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. (2005) (125)
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias (2017) (114)
Clinical diagnosis and differential diagnosis of CJD and vCJD (2002) (114)
S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease (1997) (113)
Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study (1998) (111)
Prion disease associated with a novel nine octapeptide repeat insertion in the PRNP gene. (1995) (108)
Characteristic CSF Prion Seeding Efficiency in Humans with Prion Diseases (2014) (105)
Isoform Pattern of 14‐3‐3 Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt‐Jakob Disease (1999) (104)
Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. (2008) (104)
Cerebrospinal fluid real‐time quaking‐induced conversion is a robust and reliable test for sporadic creutzfeldt–jakob disease: An international study (2016) (102)
Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid (1996) (99)
Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease (2021) (96)
The real-time quaking-induced conversion assay for detection of human prion disease and study of other protein misfolding diseases (2016) (96)
Sporadic Creutzfeldt–Jakob disease and surgery: A case–control study using community controls (2002) (94)
R47H TREM2 variant increases risk of typical early-onset Alzheimer's disease but not of prion or frontotemporal dementia (2014) (92)
High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease. (2014) (92)
Pattern of Cortical Changes in Sporadic Creutzfeldt-Jakob Disease (2007) (91)
European surveillance on Creutzfeldt-Jakob disease: a case-control study for medical risk factors. (2000) (90)
Clinical findings and diagnostic tests in the MV2 subtype of sporadic CJD. (2006) (90)
Clinical Features of Rapidly Progressive Alzheimer’s Disease (2010) (86)
Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic (2016) (83)
Clinical features and diagnosis of the MM2 cortical subtype of sporadic Creutzfeldt-Jakob disease. (2006) (82)
β‐amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease (2003) (82)
Positron emission tomography with [18F]FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD) (2002) (81)
Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis (2007) (79)
Isolated Cortical Signal Increase on MR Imaging as a Frequent Lesion Pattern in Sporadic Creutzfeldt-Jakob Disease (2008) (78)
Phenotypic variability in fatal familial insomnia (D178N-129M) genotype (1998) (76)
Seeding variability of different alpha synuclein strains in synucleinopathies (2019) (75)
Cerebrospinal fluid biomarkers in human genetic transmissible spongiform encephalopathies (2009) (74)
Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. (2000) (73)
Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. (2012) (71)
Fatal familial insomnia: Clinical features and early identification (2008) (70)
Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance (2018) (70)
Hereditary Human Prion Diseases: an Update (2017) (69)
Immunochemical determination of cellular prion proteinin plasma from healthy subjects and patients withsporadic CJD or other neurologic diseases (2001) (68)
14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypes (2009) (67)
Radiological assessment of Creutzfeldt-Jakob disease (2007) (66)
Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. (2009) (65)
Sporadic Creutzfeldt–Jakob disease (2005) (65)
Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia (2016) (65)
8-OHdG in Cerebrospinal Fluid as a Marker of Oxidative Stress in Various Neurodegenerative Diseases (2009) (64)
CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies (2007) (64)
Subtype and Regional-Specific Neuroinflammation in Sporadic Creutzfeldt–Jakob Disease (2014) (62)
Significant association of a M129V independent polymorphism in the 5′ UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study (2006) (62)
Doxycycline in early CJD: a double-blinded randomised phase II and observational study (2016) (61)
Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis (2013) (61)
Detection of Infectivity in Blood of Persons with Variant and Sporadic Creutzfeldt-Jakob Disease (2014) (60)
Cerebrospinal fluid neurofilament light levels in neurodegenerative dementia: Evaluation of diagnostic accuracy in the differential diagnosis of prion diseases (2018) (58)
Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia (2020) (58)
Cerebral gene expression profiles in sporadic Creutzfeldt–Jakob disease (2005) (58)
Proteomics approach to identify the interacting partners of cellular prion protein and characterization of Rab7a interaction in neuronal cells. (2011) (54)
PrP mRNA and protein expression in brain and PrPc in CSF in Creutzfeldt-Jakob disease MM1 and VV2 (2013) (52)
Therapeutic approaches for prion disorders (2007) (51)
Rapidly progressive Alzheimer's disease: a multicenter update. (2012) (51)
Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls (2010) (51)
Effect of Metformin on Adult Hippocampal Neurogenesis: Comparison with Donepezil and Links to Cognition (2017) (50)
Evaluation of α-synuclein as a novel cerebrospinal fluid biomarker in different forms of prion diseases (2017) (47)
Clinical findings in sporadic Creutzfeldt-Jakob disease correlate with thalamic pathology. (2002) (47)
A proposal of new diagnostic pathway for fatal familial insomnia (2013) (46)
Interleukin 4 and interleukin 10 levels are elevated in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. (2005) (46)
Increase of neuron-specific enolase in patients with Creutzfeldt-Jakob disease (1999) (46)
Sporadic Creutzfeldt-Jakob disease. (2011) (45)
Pro- and anti-inflammatory cytokines in the CSF of patients with Creutzfeldt–Jakob disease (2006) (45)
Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease. (2013) (44)
Overexpression of cellular prion protein alters postischemic Erk1/2 phosphorylation but not Akt phosphorylation and protects against focal cerebral ischemia. (2008) (44)
Intensity of human prion disease surveillance predicts observed disease incidence (2013) (44)
TGF-β 1 enhances neurite outgrowth via regulation of proteasome function and EFABP (2010) (44)
Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies. (1997) (44)
Beta-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. (2003) (43)
CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD (2019) (41)
Ascertainment bias causes false signal of anticipation in genetic prion disease. (2014) (41)
Immunotherapy in prion disease (2013) (41)
Similarities between forms of sheep scrapie and Creutzfeldt-Jakob disease are encoded by distinct prion types. (2009) (39)
Physiological role of the cellular prion protein (PrPc): protein profiling study in two cell culture systems. (2008) (39)
Clinical course in young patients with sporadic Creutzfeldt–Jakob disease (2005) (39)
Age at onset in genetic prion disease and the design of preventive clinical trials (2019) (39)
Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer’s disease and multiple sclerosis (2014) (38)
Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk (2012) (38)
Polymorphisms within the prion-like protein gene (Prnd) and their implications in human prion diseases, Alzheimer's disease and other neurological disorders (2001) (38)
Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach (2020) (38)
Apolipoprotein E in Creutzfeldt-Jakob disease (1995) (38)
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease (2021) (38)
Dementia with Lewy Bodies: Molecular Pathology in the Frontal Cortex in Typical and Rapidly Progressive Forms (2017) (37)
Genetic epidemiology of Creutzfeldt-Jakob disease in Europe. (2001) (36)
Loss of Prion Protein Leads to Age-Dependent Behavioral Abnormalities and Changes in Cytoskeletal Protein Expression (2014) (36)
Iatrogenic Creutzfeldt‐Jakob Disease with Florid Plaques (2003) (36)
Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease (2018) (36)
Immunoglobulins and virus‐specific antibodies in patients with Creutzfeldt–Jakob disease * (2005) (35)
Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays (2020) (35)
Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease (2017) (35)
Cytosolic Trapping of a Mitochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies. (2019) (35)
Enhanced Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease (2013) (35)
Cerebral microbleeds in early Alzheimer’s disease (2016) (34)
CSF biomarkers in neurodegenerative and vascular dementias (2016) (34)
Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development (2019) (34)
Sporadic Creutzfeldt-Jakob disease: clinical and diagnostic characteristics of the rare VV1 type (2005) (34)
Cerebrospinal fluid tau levels are a marker for molecular subtype in sporadic Creutzfeldt-Jakob disease (2015) (33)
Creutzfeldt-Jakob disease in a patient with an R208H mutation of the prion protein gene (PRNP) and a 17-kDa prion protein fragment (2005) (33)
Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations (2017) (33)
C‐reactive protein and IL‐6: new marker proteins for the diagnosis of CJD in plasma? (2001) (32)
Human transmissible spongiform encephalopathies in eleven countries: diagnostic pattern across time, 1993–2002 (2006) (32)
Urinary α1-Antichymotrypsin: A Biomarker of Prion Infection (2008) (32)
Alzheimer’s Disease: Genetic Polymorphisms and Rate of Decline (2012) (32)
Cerebrospinal α-synuclein in α-synuclein aggregation disorders: tau/α-synuclein ratio as potential biomarker for dementia with Lewy bodies (2016) (31)
Therapeutic trials in human transmissible spongiform encephalo-pathies: recent advances and problems to address. (2009) (31)
Cytokine profiles and the role of cellular prion protein in patients with vascular dementia and vascular encephalopathy (2015) (31)
Clinical and differential diagnosis of Creutzfeldt-Jakob disease. (2000) (31)
Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie (2016) (30)
Increased Lipid Peroxidation in Cerebrospinal Fluid and Plasma from Patients with Creutzfeldt–Jakob Disease (2002) (30)
Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study (2020) (29)
Anti-LRP/LR Antibody W3 Hampers Peripheral PrPSc Propagation in Scrapie Infected Mice (2007) (29)
Brain-derived proteins in the CSF, do they correlate with brain pathology in CJD? (2006) (28)
SFPQ and Tau: critical factors contributing to rapid progression of Alzheimer’s disease (2020) (27)
Movement disturbances in the differential diagnosis of Creutzfeldt‐Jakob disease (2009) (27)
Age of onset in genetic prion disease and the design of preventive clinical trials (2018) (27)
Akinetic mutism as a classification criterion for the diagnosis of Creutzfeldt-Jakob disease (1998) (27)
Plasma YKL-40 in the spectrum of neurodegenerative dementia (2019) (27)
Diagnostic challenges in rapidly progressive dementia (2018) (26)
A Genome Wide Association Study Links Glutamate Receptor Pathway to Sporadic Creutzfeldt-Jakob Disease Risk (2015) (26)
Subtype and regional regulation of prion biomarkers in sporadic Creutzfeldt–Jakob disease (2015) (26)
Evidence for a Pathogenic Role of Different Mutations at Codon 188 of PRNP (2008) (25)
Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges (2018) (25)
Health professions and risk of sporadic Creutzfeldt-Jakob disease, 1965 to 2010. (2012) (25)
MRI and clinical syndrome in dura materrelated Creutzfeldt-Jakob disease (2009) (25)
Clinical findings and diagnosis in genetic prion diseases in Germany (2015) (25)
Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease (2017) (25)
Fatal familial insomnia: mitochondrial and protein synthesis machinery decline in the mediodorsal thalamus (2017) (25)
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia (2017) (25)
Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study (2020) (25)
Apolipoprotein E phenotype frequency and cerebrospinal fluid concentration are not associated with Creutzfeldt-Jakob disease. (1996) (24)
MRI in the classical MM1 and the atypical MV2 subtypes of sporadic CJD: an inter‐observer agreement study (2008) (24)
Strain-Specific Altered Regulatory Response of Rab7a and Tau in Creutzfeldt-Jakob Disease and Alzheimer’s Disease (2016) (24)
Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy (2018) (24)
Familial Creutzfeldt‐Jakob disease with a novel 120‐bp insertion in the prion protein gene (1999) (24)
Magnetic Resonance Imaging in E200K and V210I Mutations of the Prion Protein Gene (2013) (23)
Behavioral abnormalities in prion protein knockout mice and the potential relevance of PrPC for the cytoskeleton (2014) (23)
Quantification of CSF biomarkers using an electrochemiluminescence-based detection system in the differential diagnosis of AD and sCJD (2015) (23)
Association of prion protein genotype and scrapie prion protein type with cellular prion protein charge isoform profiles in cerebrospinal fluid of humans with sporadic or familial prion diseases (2014) (23)
CSF Biomarkers and Neuropsychological Profiles in Patients with Cerebral Small-Vessel Disease (2014) (23)
Mitochondrial DNA differentiates Alzheimer's disease from Creutzfeldt-Jakob disease (2016) (23)
Cellular prion protein overexpression disturbs cellular homeostasis in SH-SY5Y neuroblastoma cells but does not alter p53 expression: a proteomic study (2010) (22)
Codon 129 polymorphism and the E200K mutation do not affect the cellular prion protein isoform composition in the cerebrospinal fluid from patients with Creutzfeldt–Jakob disease (2010) (22)
Altered Mitochondria, Protein Synthesis Machinery, and Purine Metabolism Are Molecular Contributors to the Pathogenesis of Creutzfeldt–Jakob Disease (2016) (22)
Cellular prion protein directly interacts with and enhances lactate dehydrogenase expression under hypoxic conditions (2015) (22)
Effect of Cavtratin, a Caveolin-1 Scaffolding Domain Peptide, on Oligodendroglial Signaling Cascades (2011) (22)
Blood Transfusion and Spread of Variant Creutzfeldt-Jakob Disease (2007) (22)
First symptom and initial diagnosis in sporadic CJD patients in Germany (2014) (22)
Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis (2018) (22)
Cerebrospinal fluid neurofilament light in suspected sporadic Creutzfeldt-Jakob disease (2019) (21)
Creutzfeldt–Jakob disease and oxidative stress (2000) (21)
Psychiatric symptoms in patients with sporadic Creutzfeldt-Jakob disease in Germany. (2015) (21)
The 14-3-3 brain protein and transmissible spongiform encephalopathy. (1997) (20)
Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases (2018) (20)
Identification of new molecular alterations in fatal familial insomnia. (2016) (20)
Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease (2020) (20)
Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease (2019) (20)
DNA versus RNA oxidation in Parkinson’s disease: Which is more important? (2018) (19)
Impact of vCJD on blood supply. (2007) (19)
Follow-Up Investigations of Tau Protein and S-100B Levels in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease (2005) (19)
A prognostic model for overall survival in sporadic Creutzfeldt‐Jakob disease (2020) (19)
Codon 129 polymorphism specific cerebrospinal fluid proteome pattern in sporadic Creutzfeldt-Jakob disease and the implication of glycolytic enzymes in prion-induced pathology. (2010) (19)
Brain biopsy in patients with suspected Creutzfeldt-Jakob disease. (2008) (19)
Impact of the cellular prion protein on amyloid-β and 3PO-tau processing. (2013) (19)
Cerebrospinal fluid markers in the differentiation of molecular subtypes of sporadic Creutzfeldt−Jakob disease (2016) (18)
Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs (2017) (18)
Functional MRI activation in response to panic-specific, non-panic aversive, and neutral pictures in patients with panic disorder and healthy controls (2016) (18)
Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study (2018) (18)
Cerebrospinal fluid markers analysis in the differential diagnosis of dementia with Lewy bodies and Parkinson’s disease dementia (2018) (18)
Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases (2020) (18)
A new paradigm for diagnosis of neurodegenerative diseases: peripheral exosomes of brain origin (2022) (17)
Anchorless 23–230 PrPC Interactomics for Elucidation of PrPC Protective Role (2014) (17)
Increased albumin CSF/serum ratio in dementia with Lewy bodies (2015) (17)
Diagnostic problems during late course in Creutzfeldt-Jakob disease (2003) (17)
Dura Mater Graft-Associated Creutzfeldt-Jakob Disease: The First Case in Korea (2011) (17)
Electroconvulsive therapy selectively enhances amyloid β 1–42 in the cerebrospinal fluid of patients with major depression: A prospective pilot study (2016) (17)
Partial verification bias and incorporation bias affected accuracy estimates of diagnostic studies for biomarkers that were part of an existing composite gold standard. (2016) (16)
Investigating the Association of ApoE Genotypes with Blood-Brain Barrier Dysfunction Measured by Cerebrospinal Fluid-Serum Albumin Ratio in a Cohort of Patients with Different Types of Dementia (2013) (16)
A novel three extra-repeat insertion in the prion protein gene (PRNP) in a patient with Creutzfeldt-Jakob disease (2004) (16)
A novel subtype of Creutzfeldt–Jakob disease characterized by a small 6 kDa PrP fragment (2007) (16)
Familial Creutzfeldt-Jakob disease with a novel 120-bp insertion in the prion protein gene. (1999) (16)
Novel PRNP mutation in a patient with a slow progressive dementia syndrome. (2008) (16)
Sporadic Creutzfeldt–Jakob disease subtype-specific alterations of the brain proteome: Impact on Rab3a recycling (2012) (16)
MicroRNA Expression in the Locus Coeruleus, Entorhinal Cortex, and Hippocampus at Early and Middle Stages of Braak Neurofibrillary Tangle Pathology (2017) (16)
Human transmissible spongiform encephalopathies. (1998) (16)
Creutzfeldt-Jakob disease associated with an R148H mutation of the prion protein gene (2005) (15)
MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives (2018) (15)
Molecular evidence of founder effects of fatal familial insomnia through SNP haplotypes around the D178N mutation (2008) (15)
Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies (2017) (15)
[Diffusion-weighted MRI in patients with Creutzfeldt-Jakob disease]. (2000) (15)
Mutual effects of caveolin and nerve growth factor signaling in pig oligodendrocytes (2009) (15)
Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis (2020) (15)
S1 guidelines “lumbar puncture and cerebrospinal fluid analysis” (abridged and translated version) (2020) (15)
Clinical aspects of common genetic Creutzfeldt-Jakob disease (2012) (15)
Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity (2019) (15)
Genetic prion disease with codon 196 PRNP mutation: clinical and pathological findings (2011) (15)
Differential Diagnosis of Rapid Progressive Dementia (2010) (14)
Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease. (2011) (14)
Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease (2022) (14)
The Priority position paper: Protecting Europe's food chain from prions (2016) (14)
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease (2021) (14)
Biosorption behavior and proteomic analysis of Escherichia coli P4 under cadmium stress. (2017) (13)
Cerebrospinal Fluid Apolipoprotein E Concentration and Severity of Cognitive Impairment in Patients With Newly Diagnosed Alzheimer’s Disease (2014) (13)
Alzheimer's Disease - Challenges for the Future (2015) (13)
Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases (2018) (13)
Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie (2018) (13)
Pulvinar Sign in Wernicke's Encephalopathy (2010) (12)
Prion Protein Interactome: Identifying Novel Targets in Slowly and Rapidly Progressive Forms of Alzheimer's Disease. (2017) (12)
Selenium speciation analysis in the cerebrospinal fluid of patients with Parkinson's disease. (2019) (12)
Ecto-GPR37: a potential biomarker for Parkinson’s disease (2021) (12)
Cathepsin D (C224T) Polymorphism in Sporadic and Genetic Creutzfeldt-Jakob Disease (2010) (12)
Cytoskeleton-Associated Risk Modifiers Involved in Early and Rapid Progression of Sporadic Creutzfeldt-Jakob Disease (2017) (12)
Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry* (2019) (12)
Neural cell-surface and intracellular autoantibodies in patients with cognitive impairment from a memory clinic cohort (2021) (12)
RNA editing alterations define manifestation of prion diseases (2019) (12)
CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD (2018) (12)
Prion Peptide Uptake in Microglial Cells – The Effect of Naturally Occurring Autoantibodies against Prion Protein (2013) (11)
Plasminogen activities and concentrations in patients with sporadic Creutzfeldt–Jakob disease (2004) (11)
Rapidly progressive dementias — aetiologies, diagnosis and management (2022) (11)
Cellular Prion Protein Mediates α‐Synuclein Uptake, Localization, and Toxicity In Vitro and In Vivo (2021) (11)
Diagnostic profiles of patients with late-onset Creutzfeldt–Jakob disease differ from those of younger Creutzfeldt–Jakob patients: a historical cohort study using data from the German National Reference Center (2014) (11)
Cerebrospinal fluid apolipoprotein E concentration and progression of Alzheimer's disease. (2014) (11)
Comprehensive Neuropathologic Analysis of Genetic Prion Disease Associated With the E196K Mutation in PRNP Reveals Phenotypic Heterogeneity (2011) (11)
Neuropsychological Symptoms in Sporadic Creutzfeldt-Jakob Disease Patients in Germany. (2017) (11)
CSF prion protein concentration and cognition in patients with Alzheimer disease (2013) (11)
[Epidemiology and clinical symptomatology of Creutzfeldt-Jakob disease]. (2002) (10)
Molecular subtype-specific clinical diagnosis of prion diseases. (2007) (10)
Transcription of Alu DNA elements in blood cells of sporadic Creutzfeldt-Jakob disease (sCJD) (2010) (10)
Laboratory Diagnosis of Creutzfeldt-Jakob Disease. (2022) (10)
Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress (2016) (10)
Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease (2020) (10)
Desmoplakin as a Potential Candidate for Cerebrospinal Fluid Marker to Rule Out 14-3-3 False Positive Rates in Sporadic Creutzfeldt-Jakob Disease Differential Diagnosis (2011) (10)
TREM2 expression in the brain and biological fluids in prion diseases (2021) (10)
CR1 is potentially associated with rate of decline in sporadic Alzheimer’s disease (2014) (10)
On the issue of transmissibility of Alzheimer disease (2012) (10)
The German FFI Cases (1998) (10)
The effect of stress on the onset and progression of Creutzfeldt–Jakob disease: Results of a German pilot case–control study (1999) (9)
Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients (2016) (9)
Increased frequency of positive family history of dementia in sporadic CJD (2009) (9)
Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies (2021) (9)
ApoE Distribution and Family History in Genetic Prion Diseases in Germany (2007) (9)
Molecular basis of Cd+2 stress response in Candida tropicalis (2017) (9)
Filtration of protein aggregates increases the accuracy for diagnosing prion diseases in brain biopsies. (2013) (9)
Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease (2018) (9)
Neurochemical dementia diagnostics - Interlaboratory variation of analysis, reference ranges and interpretations in the European CSF Survey of INSTAND (2014) (8)
Detection of proteinase K resistant proteins in the urine of patients with Creutzfeldt-Jakob and other neurodegenerative diseases (2008) (8)
Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency (2019) (8)
The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid (2019) (8)
Successful treatment of musical hallucinations with the acetylcholinesterase inhibitor donepezil. (2012) (8)
Stratification by Genetic and Demographic Characteristics Improves Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers in Rapidly Progressive Dementia. (2016) (8)
Subtype-specific synaptic proteome alterations in sporadic Creutzfeldt-Jakob disease. (2013) (8)
Variably protease‐sensitive prionopathy presenting within ALS/FTD spectrum (2018) (8)
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease (2021) (8)
Amplification and Detection of Minuscule Amounts of Misfolded Prion Protein by Using the Real-Time Quaking-Induced Conversion. (2018) (7)
Therapies for prion diseases. (2019) (7)
Clinical findings and diagnostic tests in Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease. (2004) (7)
Cerebrospinal fluid in Creutzfeldt-Jakob disease. (2017) (7)
Low-abundant cerebrospinal fluid proteome alterations in dementia with Lewy bodies. (2013) (7)
Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein (2018) (7)
Rare structural genetic variation in human prion diseases (2015) (7)
Distribution of microRNA profiles in pre-clinical and clinical forms of murine and human prion disease (2021) (7)
Clinical Features and Diagnosis of the MM 2 Cortical Subtype of Sporadic Creutzfeldt-Jakob Disease (2006) (7)
[Early and differential diagnosis of Creutzfeldt-Jakob disease]. (2002) (7)
Report about Four Novel Mutations in the Prion Protein Gene (2013) (6)
Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients (2019) (6)
Cerebrospinal fluid biomarkers in human prion diseases (2010) (6)
Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry. (2019) (6)
Cellular prion protein mediates early apoptotic proteome alternation and phospho-modification in human neuroblastoma cells (2017) (6)
Oligodendroglial Process Formation is Differentially Affected by Modulating the Intra- and Extracellular Cholesterol Content (2012) (6)
Human prion diseases: progress in clinical trials (2013) (6)
Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease (2020) (6)
Progress in CSF biomarker discovery in sCJD (2016) (6)
Cellular Prion Protein (PrPc) and Hypoxia: True to Each Other in Good Times and in Bad, in Sickness, and in Health (2016) (6)
Molecular Profiles of Amyloid-β Proteoforms in Typical and Rapidly Progressive Alzheimer’s Disease (2021) (5)
Pre-progression rates in Alzheimer's disease revisited. (2013) (5)
Neurodegenerative Proteinopathies in the Proteoform Spectrum—Tools and Challenges (2021) (5)
Neurochemical Dementia Diagnostics Ã¢ÂÂ Interlaboratory Variation ofAnalysis, Reference Ranges and Interpretations (2014) (5)
Cerebrospinal fluid non-phosphorylated tau in the differential diagnosis of Creutzfeldt–Jakob disease: a comparative prospective study with 14-3-3 (2019) (5)
Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy (2019) (5)
Tau Protein as a Biological Fluid Biomarker in Neurodegenerative Dementias (2018) (5)
Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer’s Disease (2022) (5)
Creutzfeldt-Jakob Disease and Homocysteine Levels in Plasma and Cerebrospinal Fluid (2005) (5)
Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage (2015) (5)
Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis (2020) (5)
Polymorphic microsatellite sites in the PRNP region point to excess of homozygotes in Creutzfeldt-Jakob disease patients. (2006) (5)
Prion protein quantification in cerebrospinal fluid as a tool for prion disease drug development (2018) (5)
Is there a role of Tau in Huntington′s disease? (2016) (5)
Epidemiology and risk factors of transmissible spongiform encephalopathies in man. (2001) (5)
A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia (2020) (5)
Isolated spasticity in sporadic Creutzfeldt-Jakob disease (2013) (5)
Chromogranin A Analysis in the Differential Diagnosis Across Lewy Body Disorders. (2020) (4)
Cerebrospinal Fluid Iron‐Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease (2021) (4)
Baseline CSF/Serum-Ratio of Apolipoprotein E and Rate of Differential Decline in Alzheimer's Disease. (2015) (4)
Report of the Working Group ‘Overall Blood Supply Strategy with Regard to Variant Creutzfeldt-Jakob Disease (vCJD)’ (2009) (4)
RT-QuIC for detection of prodromal α-synucleinopathies (2021) (4)
TREM2 VARIANTS INCREASE RISK OF TYPICAL EARLY-ONSET ALZHEIMER'S DISEASE BUT NOT OF PRION OR FRONTOTEMPORAL DEMENTIA (2014) (4)
A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease (2013) (4)
Cellular immune activation markers neopterin and beta 2-microglobulin are not elevated in the cerebrospinal fluid of patients with Creutzfeldt–Jakob disease (2011) (4)
Prion Protein Strain Diversity and Disease Pathology (2018) (4)
Diagnosis of Prion Disease: Conventional Approaches (2013) (4)
Distinct microglia profile in Creutzfeldt–Jakob disease and Alzheimer's disease is independent of disease kinetics (2018) (4)
Plasma neurofilament light chain as a biomarker for fatal familial insomnia (2022) (4)
Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases (2020) (4)
Cadmium induces GAPDH- and- MDH mediated delayed cell aging and dysfunction in Candida tropicalis 3Aer (2019) (4)
RNAs in Brain and Heart Diseases † (2020) (4)
Free caspase activity in CSF of patients with dementia (2009) (4)
Cerebrospinal fluid neurogranin as a new player in prion disease diagnosis and prognosis (2019) (4)
Plasma prion protein concentration and progression of Alzheimer disease (2014) (4)
Differenzialdiagnose rasch progredienter Demenzen (2007) (4)
[Risk factors for sporadic Creutzfeldt-Jakob disease]. (2009) (3)
The cellular prion protein and its derived fragments in human prion diseases and their role as potential biomarkers (2019) (3)
Optimization of the Real-Time Quaking-Induced Conversion Assay for Prion Disease Diagnosis (2020) (3)
Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies (2021) (3)
Epidemiology and risk factors of transmissible spongiform encephalopathies in man. (2004) (3)
Reelin Expression in Creutzfeldt-Jakob Disease and Experimental Models of Transmissible Spongiform Encephalopathies (2017) (3)
MASP‐3: a new leptomeningeal protein in the lectin pathway (2018) (3)
The role of cellular prion protein in lipid metabolism in the liver (2020) (3)
Application of capillary immunoelectrophoresis revealed an age‐ and gender‐dependent regulated expression of PrPC in liver (2015) (3)
BAMBI and CHGA in Prion Diseases: Neuropathological Assessment and Potential Role as Disease Biomarkers (2020) (3)
Variants of PLCXD3 are not associated with variant or sporadic Creutzfeldt-Jakob disease in a large international study (2016) (3)
Case 28-1999: Creutzfeldt-Jakob disease. (2000) (3)
Corrigendum: Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis (2020) (3)
A novel V272D presenilin mutation associated with logopenia, disorientation, and apraxia in an autosomal-dominant Alzheimer's disease family (2020) (3)
Cerebral small vessel disease burden and cognitive and functional outcomes after stroke: A multicenter prospective cohort study (2022) (3)
Possible Editing of Alu Transcripts in Blood Cells of Sporadic Creutzfeldt–Jakob Disease (sCJD) (2011) (3)
Validation of Plasma Neurofilament Light Chain as a Marker for α‐Synucleinopathies (2021) (3)
Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases (2022) (3)
Spongiform encephalopathy in siblings with no evidence of protease-resistant prion protein or a mutation in the prion protein gene (2013) (3)
Validation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease (2022) (3)
Cerebrospinal Fluid Based Diagnosis in Alzheimer’s Disease (2011) (2)
Correction: Evidence for a Pathogenic Role of Different Mutations at Codon 188 of PRNP (2008) (2)
[Fatal familial insomnia--a rare differential diagnosis in dementia]. (2008) (2)
Sporadic Creutzfeldt-Jakob Disease among Physicians, Germany, 1993–2018 (2020) (2)
[New variant Creutzfeldt-Jakob disease]. (2002) (2)
The prion protein and its ligands: Insights into structure-function relationships. (2022) (2)
MR intensity analysis to discriminate variant, sporadic CJD and non-CJD dementia patients (2004) (2)
Autoantibody-associated psychiatric syndromes in children: link to adult psychiatry (2021) (2)
Concordance of CSF RT-QuIC across the European Creutzfeldt-Jakob Disease surveillance network. (2022) (2)
Genetic prion disease: opportunities for early therapeutic intervention with rigorous pre-symptomatic trials (2020) (2)
Anti-pan-neurofascin antibodies induce subclass-related complement activation and nodo-paranodal damage (2022) (2)
Genome-wide association study identifies risk variants for sporadic Creutzfeldt-Jakob disease in STX6 and GAL3ST1 (2020) (2)
Transthyretin Cerebrospinal Fluid Levels in Alzheimer's Disease – Is This a Biomarker for Disease Severity? (2009) (2)
In-Frame Insertion Mutation in the SPG11 Gene Causes Autosomal Recessive Spastic Paraplegia with Thin Corpus Callosum “In A” Turkish Family with Late Age of Onset of the Phenotype (2015) (2)
Prospective CERAD Neuropsychological Assessment in Patients With Multiple System Atrophy (2022) (1)
Clinical and therapeutic aspects of prion disease. (2008) (1)
Cerebrospinal Fluid Prion Disease Biomarkers in Pre-clinical and Clinical Naturally Occurring Scrapie (2018) (1)
Investigating new treatments for Creutzfeldt–Jakob disease (2022) (1)
Novel Biomarkers and the Diagnosis of Prion Diseases (2016) (1)
[The Creutzfeld-Jakob disease. A sphinx of current neurobiology]. (1997) (1)
H Ficolin: Polymerization and Aggregation from Blood to Cerebrospinal Fluid (2017) (1)
Hypothyroidism, Congenital (2005) (1)
Role of different recombinant PrP substrates in the diagnostic accuracy of the CSF RT-QuIC assay in Creutzfeldt-Jakob disease (2022) (1)
No reactivation of JCV and CMV infections in the temporal cortex and cerebellum of sporadic Creutzfeldt-Jakob disease patients. (2014) (1)
Sporadic Creutzfeldt-Jakob disease (2012) (1)
Sporadic CJD in a patient with relaplsing-remitting multiple sclerosis on an immunomodulatory treatment. (2011) (1)
Plasma YKL-40 in the spectrum of neurodegenerative dementia (2019) (1)
Altered mRNA and Protein Expression of Monocarboxylate Transporter MCT1 in the Cerebral Cortex and Cerebellum of Prion Protein Knockout Mice (2021) (1)
[Creutzfeldt-Jakob disease: clinical and diagnostic aspects]. (2015) (1)
Supplementary Material for: Cerebrospinal Fluid Biomarker-Based Diagnosis of Sporadic Creutzfeldt-Jakob Disease: A Validation Study for Previously Established Cutoffs (2017) (1)
Validation of 14-3-3 Protein as a Marker in Sporadic Creutzfeldt-Jakob Disease Diagnostic (2015) (1)
Subtype Specific CSF Biomarkers in Sporadic Creutzfeldt-Jakob Disease (2017) (1)
Biomarkers in Cerebrospinal Fluid (2017) (1)
Development of novel elisas for the quantification of both pan-ApoE and ApoE4 proteins in CSF and blood, and ApoE ε4 phenotyping (2015) (1)
Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers (2022) (1)
ORIGINAL RESEARCH Isolated Cortical Signal Increase on MR Imaging as a Frequent Lesion Pattern in Sporadic Creutzfeldt-Jakob Disease (2008) (1)
3-36-07 Psychiatric symptoms are common in sporadic Creutzfeldt-Jakob Disease (1997) (1)
M Ficolin: Diffusion dynamics from Blood to Cerebrospinal Fluid (2018) (1)
Concordance of cerebrospinal fluid real‐time quaking‐induced conversion across the European Creutzfeldt–Jakob Disease Surveillance Network (2022) (1)
P2.028 8-OHdG in cerebrospinal fluid as a marker of oxidative stress in various neurodegenerative diseases (2009) (1)
Risk Factors for Disease Progression in Alzheimer's Disease (2011) (1)
[Brain SPECT using Tc-99m-bicisate (ECD) in rapidly progressive dementia syndrome]. (1999) (1)
Unveiling the Physical and Functional Niches of FAM26F by Analyzing Its Subcellular Localization and Novel Interacting Partners (2020) (1)
Animal TSEs and public health: What remains of past lessons? (2018) (1)
Acknowledgment to reviewers (2013) (1)
Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays (2020) (1)
[Course of anxiety, depression, and quality of life in relatives of patients with Creutzfeldt-Jakob-Disease] (1999) (1)
Molecular basis of Cd+2 stress response in Candida tropicalis (2017) (0)
Jakob disease : clinical and diagnostic aspects (0)
Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease (2015) (0)
[Clinical aspects, diagnosis and therapeutic possibilities of human prion diseases]. (2002) (0)
Prion protein oligomers cause neuronal cytoskeletal damage in rapidly progressive Alzheimer’s disease (2021) (0)
Cerebrospinal Fluid Total Prion Protein in the Spectrum of Prion Diseases (2018) (0)
Reelin Expression in Creutzfeldt-Jakob Disease and Experimental Models of Transmissible Spongiform Encephalopathies (2016) (0)
Effectiveness of donepezil in the treatment of musical hallucinations: evidence from case reports and pathophysiological considerations (2011) (0)
Transmission of vCJD Through Blood Transfusion, and Its Prevention (2007) (0)
DECIPHERING THE PROGRESSION OF ALZHEIMER’S DISEASE BY PROTEOMIC ANALYSIS (2018) (0)
Reply (2001) (0)
Tc-99m-Bicisate (ECD)-Brain-SPECT in RapicHv Progressive Dementia (1999) (0)
Prion and Prion-like Diseases in Humans (2013) (0)
Distribution of microRNA profiles in pre-clinical and clinical forms of murine and human prion disease (2021) (0)
Loss of Prion Protein Leads to Age-Dependent Behavioral Abnormalities and Changes in Cytoskeletal Protein Expression (2014) (0)
Contents Vol. 19, 2005 (2005) (0)
Subject Index Vol. 19, 2005 (2005) (0)
MASP-2 saturation curve in cerebrospinal fluid indicates local synthesis and its equilibrium with soluble and associated forms (2021) (0)
Validation of α-Synuclein as a CSF Biomarker for Sporadic Creutzfeldt-Jakob Disease (2017) (0)
Prion and Prion-like Diseases in Humans (2013) (0)
Application of real-time quaking-induced conversion in Creutzfeldt–Jakob disease surveillance (2023) (0)
Age Modifies the Association Between Apolipoprotein E Genotype and Alzheimer's Disease: A CSF Biomarker-Based Multicentric Case-Control Study (2019) (0)
[Do relatives of Creutzfeldt-Jakob patients want to become genetically enlightened?]. (1998) (0)
Cerebrospinal Fluid Total and Phosphorylated α-Synuclein in Patients with Creutzfeldt–Jakob Disease and Synucleinopathy (2018) (0)
Ligands binding to the cellular prion protein induce its protective proteolytic release with therapeutic potential in neurodegenerative proteinopathies (2021) (0)
Tissue plasminogen activator’s level in cerebrospinal fluid as a potential biomarker for Creutzfeldt Jakob disease (2007) (0)
P3-377 Cerebrospinal fluid investigations in creutzfeldt-jakob disease (2004) (0)
Proteomic Approaches to Identify the Mechanism of rapid progression of Alzheimers Disease (2017) (0)
Steroid-responsive encephalopathy in autoimmune thyroiditis (SREAT) as a differential diagnosis of Creutzfeldt-Jakob disease. (2023) (0)
[Therapeutic approaches for treatment of Creutzfeldt-Jakob disease]. (2008) (0)
Features of Steroid-Responsive Encephalopathy with Thyroid Autoantibodies (2006) (0)
SWATH Mass Spectrometry-Based CSF Proteome Profile of GBA-Linked Parkinson’s Disease Patients (2022) (0)
P2-156 Brain-derived proteins in the cerebrospinal fluid and neuropathological lesion profiles in CJD (2006) (0)
Molecular Alterations in the Cerebellum of Sporadic Creutzfeldt–Jakob Disease Subtypes with DJ-1 as a Key Regulator of Oxidative Stress (2016) (0)
Title CSF neurogranin as a neuronal damage marker in CJD : A comparative study with AD Running head Neurogranin in the CSF and brain of AD and CJD (2019) (0)
Strain-Specific Altered Regulatory Response of Rab7a and Tau in Creutzfeldt-Jakob Disease and Alzheimer’s Disease (2016) (0)
Validation of Poly(Propylene Imine) Glycodendrimers Towards Their Anti-prion Conversion Efficiency (2019) (0)
Hereditary Human Prion Diseases: an Update (2016) (0)
Characteristic CSF Prion Seeding Efficiency in Humans with Prion Diseases (2014) (0)
COMPARISON OF DIFFERENT CEREBROSPINAL FLUID BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS IN NEURODEGENERATIVE DISEASE: A CRITICAL ANALYSIS (2016) (0)
Creutzfeldt-Jakob Disease Subtype-Specific Regional and Temporal Regulation of ADP Ribosylation Factor-1-Dependent Rho/MLC Pathway at Pre-Clinical Stage (2015) (0)
Oral session 25 — Higher function disorders (3) (2005) (0)
Report on cluster of three autopsy confirmed cases of sporadic Creutzfeldt–/INS;Jakob disease from Luxembourg including videos, imaging, genetics and neuropathology (2013) (0)
Human Prion Diseases (2013) (0)
Molecular and Clinical Aspects of Protein Aggregation Assays in Neurodegenerative Diseases (2018) (0)
Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia (2020) (0)
Case Studies in Dementia: Thiamine for dementia in a young woman (2011) (0)
Cytosolic Trapping of a Mi tochondrial Heat Shock Protein Is an Early Pathological Event in Synucleinopathies Graphical (2019) (0)
7350 Correlation of magnetization transfer ( MT ) and diffusion MRI in sporadic Creutzfeldt-Jacob disease (2013) (0)
Contents Vol. 6, 2009 (2010) (0)
Prion research: past, present, and future. (2007) (0)
Increased alpha-synuclein tear fluid levels in patients with Parkinson’s disease (2020) (0)
PrP type 1 from a sporadic CJD case (2011) (0)
Kinases (Protein Kinases) (2013) (0)
67th Annual Meeting of the German Society of Neurology and 154th Meeting of the Swiss Neurological Society (2004) (0)
Inherited mtDNA variations are not strong risk factors in human prion disease (2015) (0)
Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease (2021) (0)
[Creutzfeldt-Jakob disease. A sphinx of modern neurobiology]. (1998) (0)
Interleukin 4 and Interleukin 10 in Creutzfeldt-Jakob Disease—Reply (2006) (0)
004 Validation of the diagnostic criteria for sporadic Creutzfeldt-Jakob disease (2022) (0)
Author response: Increased expression of heme-binding protein 1 early in Alzheimer's disease is linked to neurotoxicity (2019) (0)
Cytoskeleton-Associated Risk Modifiers Involved in Early and Rapid Progression of Sporadic Creutzfeldt-Jakob Disease (2017) (0)
Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers (2022) (0)
[Perspectives on medical research by relatives of patients with Creutzfeldt-Jakob disease]. (2000) (0)
Tau-protein concentrations are not elevated in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy (2019) (0)
Protein Structure and Biology (2013) (0)
[Expanded illness spectrum of human spongiform encephalopathies or prion diseases]. (1997) (0)
Prion2022-pushing the boundaries (2023) (0)
Molecular Profiles of Amyloid-β Proteoforms in Typical and Rapidly Progressive Alzheimer’s Disease (2021) (0)
A new paradigm for diagnosis of neurodegenerative diseases: peripheral exosomes of brain origin (2022) (0)
P.1.137 Autoimmune thyroiditis (AIT) and affective disorders — a prospective pilot study (2003) (0)
Ecto-GPR37: a potential biomarker for Parkinson’s disease (2021) (0)
Prion protein quantification in cerebrospinal fluid as a tool for prion disease therapeutic development (2019) (0)
P2‐203: WITHDRAWN (2018) (0)
Anchorless 23–230 PrPC Interactomics for Elucidation of PrPC Protective Role (2014) (0)
Edinburgh Explorer Cerebrospinal fluid biomarker supported diagnosis of Creutzfeldt-Jakob disease and rapid dementias (2018) (0)
YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias (2017) (0)
Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline (2022) (0)
MicroRNA Expression in the Locus Coeruleus, Entorhinal Cortex, and Hippocampus at Early and Middle Stages of Braak Neurofibrillary Tangle Pathology (2017) (0)
Effect of Metformin on Adult Hippocampal Neurogenesis: Comparison with Donepezil and Links to Cognition (2017) (0)
Oligodendroglial Process Formation is Differentially Affected by Modulating the Intra- and Extracellular Cholesterol Content (2012) (0)
CL‐K1, a Novel Lectin Pathway Component is a Leptomeningeal Protein (2017) (0)
Interleukin 4 and interleukin 10 in creutzfeldt-jakob disease. Authors' Reply (2006) (0)
Synthesis, structural characterization and study of antioxidant and anti-PrPSc properties of flavonoids and their rhenium(I)–tricarbonyl complexes (2023) (0)
New Frontiers in Alzheimer's Disease Diagnosis (2015) (0)
047 Clinicopathological characteristics impacting on survival in sporadic CJD: insights from an international autopsy-confirmed series (2022) (0)
Chapter 9 New Frontiers in Alzheimer ' s Disease Diagnosis (2018) (0)
Subject Index Vol. 6, 2009 (2010) (0)
α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies (2023) (0)
CSF/serum quotients for albumin and MASP-2 with individual CSF and serum concentrations of MASP-2 in controls and patients with barrier dysfunctions and the individual expected CSF MASP-2 and CSF MASP-2. (2020) (0)
Rapidly Progressive Behavioral Changes and Cognitive Symptoms in a 29-Year-Old Woman (2021) (0)
Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer's disease and multiple sclerosis (2014) (0)
Altered Ca2+ homeostasis induces Calpain-Cathepsin axis activation in sporadic Creutzfeldt-Jakob disease (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Inga Zerr?

Inga Zerr is affiliated with the following schools:

University of Göttingen

Inga Zerr's Academic­Influence.com Rankings

Why Is Inga Zerr Influential?

Inga Zerr's Published Works

Published Works

What Schools Are Affiliated With Inga Zerr?

Inga Zerr's AcademicInfluence.com Rankings